ArticleNano letters2026
Ultrathin PtCu Nanosheets: A New Frontier in Highly Efficient and Durable Catalysts for the Oxygen Reduction Reaction.
Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-copper alloy nanosheets supported on carbon (PtCu NS/C) with well-defined (111) facets were synthesized via a scalable one-pot method, yielding ultrathin structures with thicknesses of ∼1 nm and lateral sizes of ∼10-15 nm. As catalysts for the oxygen reduction reaction (ORR), PtCu NS/C exhibited superior performance and durability compared to those of PtCu octahedral nanoparticles (PtCu NP/C) and commercial Pt/C. In half-cell measurements, PtCu NS/C achieved a mass activity of 5.61 A mg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.